Literature DB >> 1662629

Influence of the test medium on azithromycin and erythromycin regression statistics.

A L Barry1, P C Fuchs.   

Abstract

Azithromycin and erythromycin disk test results were compared to MIC values obtained in six different media. One hundred isolates were tested in triplicate, and geometric mean MICs were plotted against arithmetic mean zone diameters and regression statistics calculated. The test media evaluated did not markedly influence MIC values, but incubation in 5-7% CO2 resulted in a two- to four-fold decrease in the activity of both drugs. For testing Haemophilus influenzae and other species that need to be tested in 5-7% CO2, interpretive breakpoints for the macrolides and azalides should be modified to compensate for the anticipated decrease in activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662629     DOI: 10.1007/bf01975838

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; C Thornsberry; T L Gavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

2.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  Disk diffusion and disk elution tests with A-56268 and erythromycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

4.  Comparative in vitro activity of the new oral macrolide azithromycin.

Authors:  H C Neu; N X Chin; G Saha; P Labthavikul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

5.  In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

7.  Interpretative criteria for the agar diffusion susceptibility test with azithromycin.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

8.  The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci.

Authors:  K T Dunkin; S Jones; A J Howard
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

  8 in total
  4 in total

1.  Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.

Authors:  L M Ednie; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans.

Authors:  R Pajukanta; S Asikainen; M Saarela; S Alaluusua; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

4.  Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for Streptococcus suis Infection.

Authors:  Yu-Feng Zhou; Hui-Min Peng; Ming-Xiao Bu; Ya-Hong Liu; Jian Sun; Xiao-Ping Liao
Journal:  Front Pharmacol       Date:  2017-09-27       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.